SILVER SPRING, Md., Feb. 14, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2011.
“I am pleased that we met our annual revenue target for 2011, which highlighted our favorable operating results for the year,” said Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer. “In addition, we have reaffirmed our revenue guidance for 2012 and 2013, as revenues from our commercial product lines continue to grow.”
Total revenues for the quarter ended December 31, 2011 were $195.2 million, up from $163.7 million for the quarter ended December 31, 2010. Net income for the quarter ended December 31, 2011 was $43.2 million or $0.79 per basic share, compared to $9.5 million or $0.17 per basic share for the quarter ended December 31, 2010. For the year ended December 31, 2011, we had net income of $217.9 million, or $3.81 per basic share and $3.67 per diluted share, compared to $105.9 million, or $1.89 per basic share and $1.78 per diluted share, for the year ended December 31, 2010. Earnings before non-cash charges(1) for the quarter ended December 31, 2011 were $87.5 million or $1.61 per basic share, compared to $72.7 million or $1.27 per basic share for the quarter ended December 31, 2010.
